1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research on Short-Lived and Long-Lived Plasma Cells in Humans is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). This topic encourages applications to understand the biology of Short-Lived Plasma Cells (SLPC) and Long-Lived Plasma Cells (LLPC) through characterization of plasma cell phenotypes and function in human health and disease.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from an opportunity page that may no longer be available. Verify current details with the funder.
Research on Short-Lived and Long-Lived Plasma Cells in Humans | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health Research on Short-Lived and Long-Lived Plasma Cells in Humans When beginning your next investigator-initiated application, consider the following NIH highlighted topic. The area of science described below is of interest to the listed NIH Institutes, Centers, and Offices (ICOs).
This is not a notice of funding opportunity (NOFO). Apply through an appropriate NIH Parent Funding Announcement or another broad NIH opportunity available on Grants. gov .
Learn how to interpret and use Highlighted Topics . Post Date: September 10, 2025 Expiration Date: September 10, 2027 This topic encourages applications to understand the biology of Short-Lived Plasma Cells (SLPC) and Long-Lived Plasma Cells (LLPC) through characterization of plasma cell phenotypes and function in human health and disease.
The continuous production of antibodies by LLPC is critical for life-long protective humoral immunity because it does not require restimulation with antigen, unlike the requirements to activate memory B cells.
However, LLPC also produce antibodies that: Mediate some autoimmune diseases Promote allergic responses Mediate organ/tissue transplant rejection Limit patient access to organ transplantation via pre-sensitization LLPC cannot be easily depleted by most drugs currently used to deplete B cells.
In contrast, SLPC have reduced survival programming, generally produce lower affinity antibodies, and are susceptible to B cell depletion therapies. LLPC may arise from a subset of SLPC or from distinct differentiation pathways compared to SLPC; although details of the pathways, mediators, and mechanisms of SLPC and LLPC generation remain to be elucidated.
This topic encourages applications that include: Ex vivo analysis of human samples New approach methodologies (NAMs) Computational modeling of plasma cells in human health and disease Central Scientific Contact: National Institute of Allergy and Infectious Diseases (NIAID) This topic will provide foundational information for rational vaccine design to promote Long-Lived Plasma Cells (LLPC) for durable immunity; diminish LLPC or their activity in autoimmune and allergic diseases, and organ transplantation; or redirect plasma cell fate differentiation to the Short-Lived Plasma Cell (SLPC) population.
Examples of research areas associated with protective or pathogenic immune responses in infectious, immune-mediated or allergic diseases include: Identification/characterization of precursor subsets of SLPC or LLPC. Characterization of tissue sites and local factors that promote bone marrow engraftment, differentiation, and persistence or residence at alternative sites, e.g., mucosa.
Effects of host factors (age, microbiome, etc) on SLPC and LLPC differentiation and function. Comparison of antigen types and formats (soluble, membrane bound) promoting LLPC vs SLPC. National Institute on Aging (NIA) Examples of research areas relevant to the National Institute on Aging (NIA): Changes in the biology of plasma cell subpopulations during aging.
Functional impact of aging phenotypes such as cardiac amyloidosis, frailty, and cognitive decline in plasma cell disorders. Geroscience interventions to enhance effective immune response, delay or potentially reverse immune aging in patients with plasma cell disorders. Mulualem E.
Tilahun, D. V. M.
, Ph. D.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Office of Research on Women's Health (ORWH) The Office of Autoimmune Disease Research in the Office of Research on Women’s Health (OADR-ORWH) is interested in research focusing on: Understanding the relationship between Short-Lived Plasma Cells (SLPC)and Long-Lived Plasma Cells (LLPC) and how LLPC mediates autoantibody production in pre-clinical autoimmunity and autoimmune disease Study the sex influences in vaccine research utilizing the new approach methodologies (NAMs) and computational modeling of plasma cells in human health and disease.
Accelerating scientific discovery in diagnosis, treatment, prevention, and cures and enhancing health for people with autoimmune disease. This office does not award grants. Applications must be relevant to the objectives of at least one of the participating NIH Institutes and Centers listed in this topic.
Victoria Shanmugam, MBBS, MRCP, FACR, CCD For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: Investigator-initiated applications from various institutions, including academic and research institutions. Confirm the full requirements in the official notice before applying.
Applications for Research on Short-Lived and Long-Lived Plasma Cells in Humans are due September 10, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Research on Short-Lived and Long-Lived Plasma Cells in Humans is funded by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleRFA-AI-28-005 recompetes NIAID's Immune Tolerance Network as a single UM1 cooperative agreement: $27M committed in FY2028, budgets capped at $23M a year in direct costs, a mandatory 7-year project period, one application per institution, and a January 29, 2027 deadline. The winner inherits roughly 20 ongoing trials and about 200 sub-agreements.
Read articleNIAID's RFA-AI-28-024 funds preclinical malaria vaccines, from AI-guided design to cGMP lots, through a phased R61/R33. It allows one application per institution, bars foreign subawards, and excludes GLP tox.
Read article